Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by goldtechon Aug 06, 2024 1:14pm
184 Views
Post# 36166185

The Game Begins

The Game BeginsYou are witnessing the highest levels of greed, ignorance and manipulation. So where are we? Phase 1B will start in about 60 days and that will dose 3 levels of patients, early, middle and late stage. In 6 months , probably 8 months from dosing we will get the results, show efficacy higher than 25% with no side effects and you have a win for AD. Remember Biogen increased its market cap by 40 Billion on the same news, will that happen, not likely, but a good rise regardless. Now here is what we can hope for, a joint Venture with huge cash upfront and huge milestones and 20% or more of net sales. The problem here is ignorance and that's our management team, very pathetic bunch. Now manipulation and greed takes over and if they are in this game to make all they can, then they will exercise all their warrants and direct the course of the company. The only problem I see here is deals done under the table and price fixing. If we prove that the collective coordinates work, then game on for PD, ALS, frontal temporal dementia and MSA. This this the best outcome, time will tell.
<< Previous
Bullboard Posts
Next >>